Rocket Pharmaceuticals granted orphan product designation for RP-A601 by EC

Rocket Pharmaceuticals announced that the European Commission, or EC, based on an opinion issued by the Committee for Orphan Medicinal Products, or COMP, of the European Medicines Agency, or EMA, has granted orphan medicinal product designation for RP-A601, the company’s adeno-associated virus-based gene therapy candidate for the treatment of plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM).